Neuromodulation and Cognitive Training for Substance Use Disorders

Description

The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve treatment outcomes.

Conditions

Stimulant Use, Alcohol Use Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve treatment outcomes.

Neuromodulation and Cognitive Training for Substance Use Disorders

Neuromodulation and Cognitive Training for Substance Use Disorders

Condition
Stimulant Use
Intervention / Treatment

-

Contacts and Locations

Minneapolis

University of Minnesota Fairview, Minneapolis, Minnesota, United States, 55454

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 3 weeks at study enrollment
  • * Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study.
  • * Able to provide written consent and comply with study procedures.
  • * Meets the MINI 7 diagnostic criteria for either stimulant use disorder (SUD) or alcohol use disorder (AUD).
  • * Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, HIV)
  • * Over 9 months of abstinence from substance use
  • * A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)
  • * Presence of a condition that would render study measures difficult or impossible to administer or interpret
  • * Age outside the range of 18 to 65
  • * Primary current substance use disorder diagnosis (according to MINI 7 diagnostic criteria) for a substance other than stimulant or alcohol, except for caffeine or nicotine (Nicotine use will be recorded but is not exclusionary)
  • * Entrance to the treatment program under a court mandate. (i.e. legally incarcerated)
  • * History of ECT or cortical energy exposure within the past 6 months, including participation in any other neuromodulation studies

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Minnesota,

Kelvin Lim, MD, PRINCIPAL_INVESTIGATOR, University of Minnesota

Study Record Dates

2025-09-01